Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 0.81 |
| ▸ | RAB9A | P51151 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.79 |
| ▸ | MITF | O75030 | 1/20 | 0.79 |
| ▸ | XBP1 | P17861 | 1/20 | 0.79 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.79 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847083 | 0.91 | KDR (0.84) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL19616459 | 0.90 | KDR (0.81) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL29647749 | 0.90 | KDR (0.81) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL846685 | 0.90 | KDR (0.81) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL845978 | 0.88 | KDR (0.79) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL846216 | 0.88 | NPC1 (1.00) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL4936436 | 0.87 | NPC1 (1.00) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL846874 | 0.87 | NPC1 (0.78) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL13991707 | 0.86 | NPC1 (0.81) | KDRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL19662759 | 0.86 | NPC1 (0.76) | KDRNPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | claimed |
| WO-2012100223-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | IRWIN JOHN (US) | 2012-07-26 | — | — | WO | claimed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | claimed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-2924028-A1 | TRPV-1 RECEPTOR ANTAGONIST COMPOUND DERIVED FROM 1,3,4-THIADIAZOLE ALKYLAMIDES AND CHALCONES | Universidad De Concepcion (CL) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014078971-A1 | TRPV-1 RECEPTOR ANTAGONIST COMPOUND DERIVED FROM 1,3,4-THIADIAZOLE ALKYLAMIDES AND CHALCONES | UNIVERSIDAD DE CONCEPCION (CL) | 2014-05-30 | — | — | WO | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8362249-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| WO-2012100223-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | IRWIN JOHN (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-6720344-B2 | BINDING TO NUCLEAR RECEPTOR PROTEINS; STIMULATING BMP-2 PROMOTER ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-13 | — | — | US | disclosed |
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | KERWIN SEAN M (US) | 2003-06-26 | — | — | US | disclosed |
| EP-0912549-A4 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | UNIV TEXAS (US) | 2002-01-02 | — | — | EP | disclosed |
| CN-1226245-A | Compound with pharmacological activity, preparation method and application thereof | UNIV TEXAS (US) | 1999-08-18 | — | — | CN | disclosed |
| EP-0912549-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048694-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | MKI67, HGF, AREG | KDR 582/4885NPC1 3040/4885RAB9A 4564/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | KDR 3653/4885NPC1 387/4885RAB9A 3405/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | KDR 704/4885NPC1 1518/4885RAB9A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.